Taste Alterations Study for Chemotherapy Side Effects

This study is looking at ways to help people manage taste changes (taste alterations or TA) that can happen during chemotherapy. It's testing two nurse-led approaches: the "Taste Alteration Self-Assessment" and "Taste Alternation Self-Management." These involve using a special tool (Chemotherapy-induced Taste Alterations Scale or CiTAS) to assess taste changes and then teaching you how to choose ways to manage your symptoms. The study wants to see if these methods help reduce the severity of taste changes, maintain your body mass index (BMI), and ensure you're eating enough. You might be able to join if you have a common type of cancer, are starting your first cycle of chemotherapy, and can read and speak English. The study aims to enroll 400 participants, but its current status is unclear.

Study design
This interventional study will randomly assign clinics to either provide usual care or usual care with added strategies for taste alteration management. It aims to enroll 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your taste alteration severity, BMI, and dietary intake will be measured through study completion, which is an average of 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06669416

Taste Alterations Study

Recruiting
NAAges 18+InterventionalTreatment
Wake Forest University Health Sciences
~400 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Taste Alteration Self-AssessmentTaste Alternation Self-Management

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Taste Alteration Severity
Measured over Through study completion, an average of 6 months.
+2 more outcomes measured
Chemotherapy Side Effects
Taste, Altered
1 sites across 1 states
Illinois1
  • Mary L Hook, PhD, RN · PRINCIPAL_INVESTIGATOR · Aurora Sinai Medical Center

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Medical diagnosis of cancer with types limited to the top cancer types \[Note: Cancer types that are rare will be excluded\]
Initiating chemotherapy (first day/first cycle) at participating clinics
English speaking/reading (without an interpreter)

Exclusion

Substitute decision-maker (activated)
History of head/neck cancer or irradiation
Known genetic/metabolic disorder impacting taste (preexisting dysgeusia)
Known eating disorder
Receiving enteral or parenteral nutrition (special nutritional needs)
Pregnant women (unique needs)
Patients with medical orders for end of life/hospice care
  • Taste Alteration SeverityThrough study completion, an average of 6 months.

    A single item question with ordinal rating will be used to confirm taste alterations and evaluate severity of TA (control) The CiTAS tool (18 item ordinal rating tool) will be used to confirm taste alterations and evaluate severity of TA (treatment)

  • Body mass index (BMI)Through study completion, an average of 6 months.

    BMI is measured to monitor for changes in weight relative to height; It is used to monitor for changes in weight that may indicate that patient is experiencing weight loss during chemotherapy treatment.

  • Dietary intakeThrough study completion, an average of 6 months.

    All patients will be asked to report number of meals/day, number of snacks/day, and number of supplements per day as an estimate of food intake during chemotherapy.